Sounds very similar to the strategy that UNS have been talking about with their needles - using their retractable sryringe to help defeat generic competition.
The Roche drugs are in the cancer/arthritis class so aren't included in the Sanofi exclusivity contract. I'd be willing to bet that Roche is the next company to partner with UNS - of course they won't announce anything until the final deal is done - exclusivity over those classes.
That sounds like confirmation that 1) there is a problem and 2) they have a solution.
I haven't heard of anyone else coming up with a defence stategy for generics so I think UNS is the logical answer.
UNS Price at posting:
78.0¢ Sentiment: Buy Disclosure: Held
